Skip to main content
OpenTrials
Completed

NCT Number: NCT02607839

Regulation of Intestinal and Hepatic Lipoprotein Particle Production by Blood Glucose in Humans

The purpose of study is to examine whether raised blood glucose enhances lipid particle production independent of effects on gastric emptying and pancreatic/ gastrointestinal hormone production.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Age range

18 year–60 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 2

Primary location

Tornto General Hospital, UHN

Toronto, Ontario, M5G 1L7, Canada

About this study

This study will be performed on healthy, lean, non-diabetic males and females who will participate two studies each in random order, 4 to 6 weeks apart. Study A: lipoprotein turnover with intravenous infusion of normal saline. Study B: lipoprotein turnover i.v infusion of glucose. In both studies, subjects will drink a liquid formula every hour to remain in a constant fed state and will be under conditions of pancreatic clamp (with the infusion of hormones somatostatin, insulin, glucagon, growth hormone). Subjects will be blinded with regard to the treatments.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Men and women, aged 18 to 60 years
  • Body mass index 20 kg/m2 to 27 kg/m2
  • Hemoglobin above 130g/L
  • Normal glucose tolerance in response to a 75g, 2-hr OGTT

Exclusion criteria

  • Subject has a history of hepatitis/hepatic disease that has been active within the previous two years.
  • Any subject with active bleeding, bleeding diathesis, clotting abnormalities or recent surgery (within past 1 month)
  • Any significant active (over the past 12 months) disease of the gastrointestinal, pulmonary, neurological, renal (Cr > 1.5 mg/dL), genitourinary, hematological systems, or has severe uncontrolled treated or untreated hypertension (sitting diastolic BP > 100 or systolic > 180).
  • History of diabetes or OGTT indicative of diabetes or impaired glucose tolerance.
  • Any history of a MI or clinically significant, active, cardiovascular history including a history of arrhythmia's or conduction delays on ECG, unstable angina, or decompensated heart failure.
  • Any laboratory values: AST > 2x ULN; ALT > 2x ULN TSH > 6 mU/l
  • Current addiction to alcohol or substances of abuse as determined by the investigator.
  • Mental incapacity, unwillingness or language barrier precluding adequate understanding or cooperation
  • Taking any prescription or non-prescription medications at the time of the study
  • Having donated blood three months prior to and three months post study procedures
  • A pregnancy test will be performed 1 to 3 days prior to each study in all female subjects. Those who test positive for pregnancy will be excluded.
  • Known allergy, hypersensitivity or contraindication to receiving study medications.

Treatment and study plan

glucose or normal saline

Biological

20% glucose solution or normal saline, intravenous infusion

Primary outcomes

  1. Production of TRL-apoB48 between treatments

    Time frame: 10 hours

Secondary outcomes

  1. Production of TRL-apoB100 between treatments

    Time frame: 10 hours

Sponsors and collaborators

Lead sponsor

University Health Network, Toronto

Other

Registry information

Important dates

Study start
2013
Primary completion
2015
Study completion
2015
First posted
Nov 18, 2015
Registry last updated
Nov 18, 2015

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.